Endoscopic treatment of vesicoureteric reflux with dextranomer/hyaluronic acid copolymer (Deflux): The National Kidney and Transplant Institute experience.
- Author:
Dator Jose Dante P.
;
Tandoc Neil Alvin
;
Torres Carlos Ramon N.
- Publication Type:Journal Article
- MeSH: Human; Male; Female; Child; Child Preschool; Infant; deflux; Endoscopy; Vesico-Ureteral Reflux-treatment, therapy, management, drug therapy; Urinary Bladder Diseases; dextranomer; dextranomer-hyaluronic acid copolymer
- From: Philippine Journal of Urology 2011;21(2):35-38
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVE: Endoscopic correction of vesicoureteral reflux has evolved as a viable alternative to open surgery. This study was conducted to review the experience of a single institution with the endoscopic Deflux procedure and assess its effectiveness in the treatment of vesicoureteral reflux.
MATERIALS AND METHODS: A retrospective review of patients who underwent endoscopic Deflux treatment for primary vesicoureteral reflux (VUR) between January 2005 and December 2010 was performed. Data collected included: age, gender, unilateral or bilateral treatment, pre-operative grade of VUR on voiding cystourethrogram (VCUG), and the number of Deflux injections per patient.
RESULTS: Sixteen patients [7 (43.75%) males and 9 (56.25%) females] were included in this study. The ages ranged from 6 months to 8 years old with a mean age of 3.15 years. Four (25%) patients had bilateral VUR while 12 (75%) had unilateral VUR, with a total of 21 refluxing ureters. Three had Grade II reflux (14.3%), 13 had Grade III reflux (62%), 5 had Grade IV reflux (24%), and 1 had Grade V reflux (4.7%). Nineteen ureters required one injection while one ureter required two injections. There were no intraoperative nor postoperative complications noted.
CONCLUSION: At the National Kidney and Transplant Institute, endoscopic treatment of VUR with Deflux for primary VUR demonstrated a cure rate of 90%, with no associated perioperative morbidity.